March 26, 2020 / 11:05 AM / 2 months ago

BRIEF-Uniqure: Achievement Of Target Patient Dosing In Hope-B Pivotal Trial Of AMT-061 In Hemophilia B

March 26 (Reuters) - Uniqure NV:

* UNIQURE ANNOUNCES ACHIEVEMENT OF TARGET PATIENT DOSING IN HOPE-B PIVOTAL TRIAL OF AMT-061 (ETRANACOGENE DEZAPARVOVEC) IN HEMOPHILIA B Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below